Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768117 | 0.86 | PTGDR2 (0.42) | PTGS2PTGS1PTGDR2EPAS1 | |
| SCHEMBL1332654 | 0.82 | PTGDR2 (0.67) | PTGDR2 | |
| SCHEMBL4790579 | 0.82 | SMN1; SMN2 (0.48) | PTGS2PTGS1PTGDR2MEN1ALDH1A1 | |
| SCHEMBL1653023 | 0.79 | KDM4E (0.38) | PTGS2PTGS1PTGDR2ALDH1A1 | |
| SCHEMBL12777260 | 0.78 | PTGDR2 (0.39) | PTGS2PTGS1PTGDR2CYP11B1CYP11B2 | |
| SCHEMBL1650744 | 0.77 | PTGDR2 (0.40) | PTGS2PTGS1PTGDR2CYP11B1CYP11B2 | |
| SCHEMBL1333682 | 0.74 | PTGDR2 (0.46) | PTGS2PTGS1PTGDR2MEN1MAPT | |
| SCHEMBL1333433 | 0.74 | TSHR (0.50) | PTGDR2 | |
| SCHEMBL1332199 | 0.74 | MEN1 (0.57) | PTGS2PTGS1PTGDR2MEN1ALDH1A1 | |
| SCHEMBL1333432 | 0.72 | PTGDR2 (0.67) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1963259-A2 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | AstraZeneca AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007068894-A2 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | PNMT, SQOR, SMS | PTGS2 525/4885PTGS1 351/4885PTGDR2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.